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ABSTRACT 
tHGA, a geranyl acetophenone compound originally isolated from a local shrub called 
Melicope ptelefolia, has been previously reported to prevent ovalbumin-induced allergic 
airway inflammation in a murine model of allergic asthma by targeting cysteinyl leukotriene 
synthesis. Mast cells are immune effector cells involved in the pathogenesis of allergic 
diseases including asthma by releasing cysteinyl leukotrienes. The anti-asthmatic properties 
of tHGA could be attributed to its inhibitory effect on mast cell degranulation. As mast cell 
degranulation is an important event in allergic responses, this study aimed to investigate the 
anti-allergic effects of tHGA in cellular and animal models of IgE-mediated mast cell 
degranulation. For in vitro model of IgE-mediated mast cell degranulation, DNP-IgE-
sensitized RBL-2H3 cells were pre-treated with tHGA before challenged with DNP-BSA to 
induce degranulation. For IgE-mediated passive systemic anaphylaxis, Sprague Dawley rats 
were sensitized by intraperitoneal injection of DNP-IgE before challenged with DNP-BSA. 
Both in vitro and in vivo models showed that tHGA significantly inhibited the release of 
preformed mediators (β-hexosaminidase and histamine) as well as de novo mediators 
(interleukin-4, tumour necrosis factor-α, prostaglandin D2 and leukotriene C4). Pre-treatment 
of tHGA also prevented IgE-challenged RBL-2H3 cells and peritoneal mast cells from 
undergoing morphological changes associated with mast cell degranulation. These findings 
indicate that tHGA possesses potent anti-allergic activity via attenuation of IgE-mediated 
mast cell degranulation and inhibition of IgE-mediated passive systemic anaphylaxis. Thus, 
tHGA may have the potential to be developed as a mast cell stabilizer for the treatment of 
allergic diseases in the future. 
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